Eyenovia Provides Updates On Its Myopia Phase III Program And Its 2 FDA Approved Commercial Products, Mydcombi And Clobetasol
Eyenovia Provides Updates On Its Myopia Phase III Program And Its 2 FDA Approved Commercial Products, Mydcombi And Clobetasol
Eyenovia提供了其近視三期計劃及其2種經美國食品藥品管理局批准的商用產品Mydcombi和Clobetasol的最新情況
Remains on track towards accelerating development of its late-stage product candidate in the multi-billion-dollar pediatric progressive myopia market, MicroPine
在價值數十億美元的兒科進行性近視市場中，加速開發其後期候選產品MicroPine仍步入正軌
Preparing for a 3Q 2024 launch of the first new ophthalmic steroid in 15 years, clobetasol propionate ophthalmic suspension 0.05%, for the treatment of inflammation and pain following ocular surgery
爲2024年第三季度推出15年來首款新的眼科類固醇——丙酸氯倍他索眼藥混懸液做準備，用於治療眼部手術後的炎症和疼痛，0.05％
Company to host conference call and webcast today, May 15th, at 4:30 pm ET
公司將於今天，美國東部時間5月15日下午 4:30 舉辦電話會議和網絡直播
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。